BARINTHUS BIOTHERAPEUT

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

12 июн 2023 06:30:00 Источник Nasdaq GlobeNewswire

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

12 май 2023 07:00:57 Источник Nasdaq GlobeNewswire

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

17 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

28 мар 2023 07:00:11 Источник Nasdaq GlobeNewswire

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

24 мар 2023 07:06:29 Источник Nasdaq GlobeNewswire

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

20 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

30 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

21 ноя 2022 09:31:34 Источник Nasdaq GlobeNewswire

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

10 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming November Investors Conferences

09 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

07 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

02 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients

31 окт 2022 07:00:02 Источник Nasdaq GlobeNewswire

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

27 окт 2022 06:00:01 Источник Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

03 окт 2022 15:30:00 Источник Nasdaq GlobeNewswire

Vaccitech Promotes Gemma Brown as Chief Financial Officer

20 сен 2022 15:30:00 Источник Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming September Investors Conferences

07 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

09 авг 2022 15:15:00 Источник Nasdaq GlobeNewswire

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

07 июл 2022 15:15:00 Источник Nasdaq GlobeNewswire

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

22 июн 2022 05:00:00 Источник Nasdaq GlobeNewswire